4th Quarter - Report

AMERICAN SOCIETY OF HEMATOLOGY for AMERICAN SOCIETY OF HEMATOLOGY

Firm
Client
Income
—
Expenses
$30,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Public health program funding Federal research funding Advanced Research Projects Agency for Health (ARPA-H) FY 2026 NIH funding FY 2026 AHRQ funding FY 2026 CDC funding FY 2026 funding for CDC Sickle Cell Data Collection program FY 2026 funding for HRSA Sickle Cell Disease Treatment Demonstration program and Sickle Cell Disease Newborn Screening program FY 2026 funding for Defense Health Research Programs, including the Congressionally Directed Medical Research Programs (CDMRP) Impact of restructuring and reorganization of federal public health and research agencies Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304 / S. 2587) FY2026 Continuing Appropriations, Agriculture, Leg. Branch & Extensions Act (through 01/30/2026) (H.R. 5371)

LobbyistCovered position, as disclosed
TRACY BECKER ROADES —
STEPHANIE ANN KAPLAN —
SUZANNE LEOUS —

Contacted: Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); Agency for Healthcare Research & Quality (AHRQ); Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA); Defense, Dept of (DOD); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5371 (119th), H.R. 5304 (119th), S. 2587 (119th)

Medical/Disease Research/Clinical Labs MED

Sickle cell disease/trait issues Hematology/oncology treatment issues Hematology/oncology drug research and approval issues General hematology public health and research issues Open access policy for peer reviewed research journals Women's health and research Issues impacting blood supply shortages/safety Issues impacting delivery of bone marrow, peripheral blood, and cord blood Clinical trials regulations and coverage Issues impacting laboratory testing and pediatric reference intervals (PRIs) Issues impacting laboratory developed tests (LDTs) Issues impacting drug shortages FDA guidance impacting hematology Impact of restructuring and reorganization of federal public health and research agencies Issues related to vaccines and immunization practices for individuals with hematologic disorders

LobbyistCovered position, as disclosed
TRACY BECKER ROADES —
STEPHANIE ANN KAPLAN —
SUZANNE LEOUS —

Contacted: Food & Drug Administration (FDA); White House Office; Health & Human Services, Dept of (HHS); Office of Science & Technology Policy (OSTP); SENATE; Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); President of the U.S.; Defense, Dept of (DOD); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Coverage of blood transfusions under Medicare Hospice Benefit Medicare physician reimbursement issues Issues related to CAR-T/cellular and gene therapies Implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10) Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) CMS national coverage determinations Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries National Coverage Decision for hematopoietic stem cell transplantation (HSCT) for MDS Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Impact of proposed Medicaid funding cuts on hematology Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)

LobbyistCovered position, as disclosed
TRACY BECKER ROADES —
STEPHANIE ANN KAPLAN —
SUZANNE LEOUS —

Contacted: Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 879 (119th), S. 721 (119th), H.R. 5178 (119th), H.R. 3514 (119th), S. 1261 (119th), S. 1936 (119th), H.R. 4206 (119th), S. 1816 (119th)

Health Issues HCR

Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261) Extension of Affordable Care Act enhanced advance premium tax credits Issues related to H-1B visas for physician workforce

LobbyistCovered position, as disclosed
TRACY BECKER ROADES —
STEPHANIE ANN KAPLAN —
SUZANNE LEOUS —

Contacted: SENATE; Homeland Security, Dept of (DHS); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS)

Bills named: S. 1936 (119th), H.R. 5178 (119th), S. 1816 (119th), H.R. 4206 (119th), S. 721 (119th), H.R. 3514 (119th), S. 1261 (119th)

Immigration IMM

Issues related to H-1B visas for physician workforce

LobbyistCovered position, as disclosed
TRACY BECKER ROADES —
STEPHANIE ANN KAPLAN —
SUZANNE LEOUS —

Contacted: HOUSE OF REPRESENTATIVES; Homeland Security, Dept of (DHS); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.